Clinical Trial Update: A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Bryostatin for moderately to severely Alzheimer's disease has completed, with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Bryostatin-1 (bryostatin-1)

Snippet

Sponsor: Neurotrope Bioscience, Inc. | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2018-07-06